Google
Trusted Resources: News & Events
Latest announcements and gatherings
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
Individuals suffering with rare diseases had very few therapeutic options 40 years ago. But that began to change with the stroke of a pen by then-President Ronald Reagan in January 1983 when he signed the bipartisan Orphan Drug Act into law. On Jan. 4, the rare disease community will celebrate the 40th anniversary of the Orphan Drug Act (ODA) — legislation that incentivized drug companies to put more resources toward the research, development, and distribution of therapeutics for people with rare diseases, who until then had been ‘orphaned’ by the medical and scientific community.
The creation of the ODA and the founding of the National Organization for Rare Disorders (NORD) are forever intertwined. The rare patients and caregivers who started the rare advocacy movement — which convinced lawmakers to introduce orphan drug legislation — knew their work was not done after the bill became law. They formed NORD to unify the voices of the unheard within the rare disease community under the premise that a rising tide could lift all boats.
+myBinderRelated Content
-
Shine the Light on Sickle Cell – Webinarhttps://www.youtube.com/watch?v=IIG0UUO5...
-
Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatmentThe prognosis of sickle cell anemia (SCA...
-
Columbia University Medical CenterThe Division of Pediatric Hematology at ...
-
Brigham and Women’s Sickle Cell Disease ClinicEach person with sickle cell disease is ...
-
RARE Patient Advocacy SummitEach year, Global Genes convenes one of ...
-
Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French...Patients with sickle cell disease (SCD) ...
-
People With Sickle Cell Are Seen as Hypochondriacs or Drug Addicts. Even a Nine-Year-Old Has to Scream to Get the Ca...Nine year old Jacob has sickle cell dise...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.